Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions
Histone deacetylase 8 (HDAC8) is a member of class I histone deacetylases (HDACs) that catalyzes the deacetylation of both histone and non-histone proteins. Dysregulation and overexpression of HDAC8 are implicated in the development of various complex diseases, including cancer and neurodegenerative...
Hauptverfasser: | Mohammed Alrouji, Kumar Venkatesan, Mohammed S. Alshammari, Fahad A. Alhumaydhi, Sheeba Shafi, Sharaf E. Sharaf, Moyad Shahwan, Anas Shamsi |
---|---|
Format: | Artikel |
Sprache: | English |
Veröffentlicht: |
Frontiers Media S.A.
2024-11-01
|
Schriftenreihe: | Frontiers in Pharmacology |
Schlagworte: | |
Online Zugang: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1488585/full |
Ähnliche Einträge
Ähnliche Einträge
-
ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics
von: Mohammed Alrouji, et al.
Veröffentlicht: (2024-07-01) -
Virtual screening and molecular dynamics simulations identify repurposed drugs as potent inhibitors of Histone deacetylase 1: Implication in cancer therapeutics.
von: Mohammed Alrouji, et al.
Veröffentlicht: (2025-01-01) -
Identification of Potential Inhibitors of Histone Deacetylase 6 Through Virtual Screening and Molecular Dynamics Simulation Approach: Implications in Neurodegenerative Diseases
von: Anas Shamsi, et al.
Veröffentlicht: (2024-11-01) -
Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer's drug discovery.
von: Mohammed Alrouji, et al.
Veröffentlicht: (2024-01-01) -
Identifying Phosphodiesterase‐5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders
von: Mohd Shahnawaz Khan, et al.
Veröffentlicht: (2024-05-01)